Photoprotection in immunocompetent and immunocompromised people

British Journal of Dermatology

Volumn 167, Issue SUPPL. 2, 2012, Pages 85-93

  Surber, C ^a   Ulrich, C ^b   Hinrichs, B ^c   Stockfleth, E ^b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c European Skin Cancer Foundation   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEMOTRIZINOL; EUSOLEX OS; SULISOBENZONE; SUNSCREEN; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; UVINUL A PLUS; ZINC OXIDE;

ALLERGY; ARTICLE; BEHAVIOR; CANCER PREVENTION; CANCER RISK; CONTACT URTICARIA; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDUCATION; ENVIRONMENTAL PROTECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; IRRITANT DERMATITIS; NONHUMAN; PHOTOAGING; PHOTOALLERGY; PHOTOTOXICITY; PRIORITY JOURNAL; PROTECTIVE CLOTHING; RADIATION EXPOSURE; RADIATION PROTECTION; RISK FACTOR; RISK REDUCTION; SHADE; SKIN CANCER; SUN EXPOSURE; SUNBURN; SUNLIGHT PROTECTION; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY;

EID: 84865019587     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11093.x     Document Type: Article

References (69)

1. International Agency for Research on Cancer. Agents Classified by the IARC Monographs. Lyon: IARC. Available at: http://monographs.iarc.fr/ENG/ Classification/index.php (last accessed 18 April 2012).
2. El Ghissassi F, Baan R, Straif K, et al. WHO international agency for research on cancer monograph working group. A review of human carcinogens-part D: radiation. Lancet Oncol 2009; 10: 751-2.
3. Baillie L, Askew D, Douglas N, Soyer HP,. Strategies for assessing the degree of photodamage to skin: a systematic review of the literature. Br J Dermatol 2011; 165: 735-42.
4. Gonzaga ER,. Role of UV light in photodamage, skin aging, and skin cancer: importance of photoprotection. Am J Clin Dermatol 2009; 10 (Suppl. 1): 19-24.
5. Diepgen TL, Mahler V,. The epidemiology of skin cancer. Br J Dermatol 2002; 146 (Suppl. 61): 1-6.
6. Lomas A, Leonardi-Bee J, Bath-Hextall F,. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-80.
7. NÃ̧rgard C, Glud M, Gniadecki R,. Are all melanomas dangerous? Acta Derm Venereol 2011; 91: 499-503.
8. Fuglede NB, Brinck-Claussen UO, Deltour I, et al. Incidence of cutaneous malignant melanoma in Denmark, 1978-2007. Br J Dermatol 2011; 165: 349-53.
9. Birch-Johansen F, Jensen A, Mortensen L, et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978-2007: rapid incidence increase among young Danish women. Int J Cancer 2010; 127: 2190-8.
10. Ekwueme DU, Guy GP Jr, Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000-2006. J Am Acad Dermatol 2011; 5 (Suppl. 1): S133-43.
11. Souza RJ, Mattedi AP, Corrêa MP, et al. An estimate of the cost of treating non-melanoma skin cancer in the state of São Paulo, Brazil. An Bras Dermatol 2011; 86: 657-62.
12. Stang A, Stausberg J, Boedeker W, et al. Nationwide hospitalization costs of skin melanoma and non-melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol 2008; 22: 65-72.
13. De Smaele E, Ferretti E, Gulino A,. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010; 11: 707-18.
14. Culver ME, Gatesman ML, Mancl EE, Lowe DK,. Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother 2011; 45: 510-19.
15. Fisher DE,. UV-tanning behavior: a problem that doesn't go away. Pigment Cell Melanoma Res 2011; 24: 724.
16. Wickelgren I,. Skin biology. A healthy tan? Science 2007; 315: 1214-16.
17. Penn I,. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000; 23: 101-13.
18. Euvrard S, Kanitakis J, Claudy A,. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-91.
19. Tessari G, Naldi L, Boschiero L, et al. Incidence and clinical predictors of a subsequent non-melanoma skin cancer in solid organ transplant recipients with a first non-melanoma skin cancer: a multicenter cohort study. Arch Dermatol 2010; 146: 294-9.
20. Wisgerhof HC, Edelbroek JR, de Fijter JW, et al. Subsequent squamous- and basal-cell carcinomas in kidney-transplant recipients after the first skin cancer: cumulative incidence and risk factors. Transplantation 2010; 89: 1231-8.
21. Brewer JD, Colegio OR, Phillips PK, et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145: 1391-6.
22. Long MD, Kappelman MD, Pipkin CA,. Nonmelanoma skin cancer in inflammatory bowel disease: a review. Inflamm Bowel Dis 2011; 17: 1423-7.
23. Setshedi M, Epstein D, Winter TA, et al. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-9.
24. Matts PJ,. Solar ultraviolet radiation: definitions and terminology. Dermatol Clin 2006; 24: 1-8.
25. Bruls WAG, Slaper H, van der Leun JC, Berrens L,. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem Photobiol 1984; 40: 485-94.
26. Schwarz T, Schwarz A,. Molecular mechanisms of ultraviolet radiation-induced immunosuppression. Eur J Cell Biol 2011; 90: 560-4.
27. Norval M, Halliday GM,. The consequences of UV-induced immunosuppression for human health. Photochem Photobiol 2011; 87: 965-77.
28. Matts PJ, Fink B,. Chronic sun damage and the perception of age, health and attractiveness. Photochem Photobiol Sci 2010; 9: 421-31.
29. Stick C,. Solar time-the importance of standard time for the UV-exposure of the skin. J Dtsch Dermatol Ges 2007; 5: 788-92.
30. Hatch KL, Osterwalder U,. Garments as ultraviolet radiation screening materials. Dermatol Clin 2006; 24: 85-100.
31. Gambichler T, Laperre J, Hoffmann K,. The European standard for sun-protective clothing: EN 13758. J Eur Acad Dermatol Venereol 2006; 20: 125-30.
32. Surber C, Pittelkow M, Lautenschlager S,. Photo protection in organ transplant recipients. Curr Probl Dermatol 2012; 43: 171-96.
33. Tanner PR,. Sunscreen product formulation. Dermatol Clin 2006; 24: 53-62.
34. Lautenschlager S, Wulf HW, Pittelkow MR,. Photoprotection. Lancet 2007; 370: 528-37.
35. Surber C, Smith EW,. The mystical effects of dermatological vehicles. Dermatology 2005; 210: 157-68.
36. van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev 2006; 15: 2546-8.
37. Gordon LG, Scuffham PA, van der Pols JC, et al. Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol 2009; 129: 2766-71.
38. Dennis LK, Beane Freeman LE, Van Beck MJ,. Sunscreen use and the risk for melanoma: a quantitative review. Ann Intern Med 2003; 139: 966-78.
39. Diffey BL,. Sunscreens and melanoma: the future looks bright. Br J Dermatol 2005; 153: 378-81.
40. Green AC, Williams GM, Logan V, Strutton GM,. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29: 257-63.
41. Lazovich D, Vogel RI, Berwick M, et al. Melanoma risk in relation to use of sunscreen or other sun protection methods. Cancer Epidemiol Biomarkers Prev 2011; 20: 2583-93.
42. Couteau C, Couteau O, Alami-El Boury S, Coiffard LJ,. Sunscreen products: what do they protect us from? Int J Pharm 2011; 415: 181-4.
43. Wong T, Orton D,. Sunscreen allergy and its investigation. Clin Dermatol 2011; 29: 306-10.
44. Schlumpf M, Cotton B, Conscience M, et al. In vitro and in vivo estrogenicity of UV screens. Environ Health Perspect 2001; 109: 239-44.
45. Wang SQ, Burnett ME, Li HW,. Safety of oxybenzone: putting numbers into perspective. Arch Dermatol 2011; 147: 865.
46. Witorsch RJ, Thomas JA,. Personal care products and endocrine disruption: a critical review of the literature. Crit Rev Toxicol 2010; 40 (Suppl. 3): 1-30.
47. Burnett ME, Wang SQ,. Current sunscreen controversies: a critical review. Photodermatol Photoimmunol Photomed 2011; 27: 58-67.
48. Holick MF,. Vitamin D: a millennium perspective. J Cell Biochem 2003; 88: 187-94.
49. Matsuoka LY, Wortsman J, Hanifan N, Holick MF,. Chronic sunscreen use decreases circulating concentrations of 25-hydroxyvitamin D: a preliminary study. Arch Dermatol 1988; 124: 1802-4.
50. Farrerons J, Barnadas M, Rodriguez J,. Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentrations sufficiently either to induce changes on parathyroid function or on metabolic markers. Br J Dermatol 1998; 139: 422-7.
51. Palmer SC, McGregor DO, Strippoli GF,. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2007; 3: CD005015.
52. Holick MF, Matsuoka LY, Wortsman J,. Age, vitamin D, and solar ultraviolet. Lancet 1989; 2: 1104-5.
53. COLIPA. Guideline for Evaluating Sun Product Water Resistance. Bruxelles: The European Cosmetic, Toiletry and Perfumery Association, 2005.
54. FDA. Consumer Updates. Available at: http://www.fda.gov/ForConsumers/ ConsumerUpdates/ucm258416.htm (last accessed 18 April 2012).
55. Poh Agin P,. Water resistance and extended wear sunscreens. Dermatol Clin 2006; 24: 75-9.
56. Godar DE, Urbach F, Gasparro FP, van der Leun JC,. UV doses of young adults. Photochem Photobiol 2003; 77: 453-7.
57. Krutmann J,. Sonnenschutz: Die Korrektur eines Irrtums. Hautarzt 2003; 54: 674.
58. Diffey BL,. The impact of topical photoprotectants intended for daily use on lifetime ultraviolet exposure. J Cosmet Dermatol 2011; 10: 245-50.
59. KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney disease: improving global outcomes. Cancer of the skin and lip. Am J Transplant 2009; 9 (Suppl. 3): S84-5.
60. Ulrich C, Kanitakis J, Stockfleth E, Euvrard S,. Skin cancer in organ transplant recipients: where do we stand today? Am J Transplant 2008; 8: 2192-8.
61. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet 1999; 354: 723-9.
62. Ulrich C, Jürgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161 (Suppl. 3): 78-84.
63. Asvat Y, Cafri G, Thompson JK, Jacobsen PB,. Appearance-based tanning motives, sunbathing intentions, and sun protection intentions in adolescents. Arch Dermatol 2010; 146: 445-6.
64. Cafri G, Thompson JK, Roehrig M, et al. An investigation of appearance motives for tanning: the development and evaluation of the physical appearance reasons for tanning scale (PARTS) and its relation to sunbathing and indoor tanning intentions. Body Image 2006; 3: 199-209.
65. Montague M, Borland R, Sinclair C,. Slip! Slop! Slap! and SunSmart, 1980-2000: skin cancer control and 20 years of population-based campaigning. Health Educ Behav 2001; 28: 290-305.
66. Goulart JM, Wang SQ,. Knowledge, motivation, and behavior patterns of the general public towards sun protection. Photochem Photobiol Sci 2010; 9: 432-8.
67. Aulbert W, Parpart C, Schulz-Hornbostel R, et al. Certification of sun protection practices in a German child day-care centre improves children's sun protection-the 'SunPass' pilot study. Br J Dermatol 2009; 161 (Suppl. 3): 5-12.
68. Donovan JCH, Rosen CF, Shaw JC,. Evaluation of sun-protective practices of organ transplant recipients. Am J Transplant 2004; 4: 1852-8.
69. Ismail F, Mitchel L, Casabonne D, et al. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Br J Dermatol 2006; 155: 916-25.